KLK3 and cancer: These results led to specific cancer-screening recommendations in anti-RNA-PolIII positive patients, over a period of 2 to 5 years, including routine mammography (repeated every year) and non-invasive investigations, such as prostatic specific antigen (PSA) testing, blood stool test, and gynecological examination.